Diabetic Macular Edema (DME) Overview

Save information for later
Sign Up

Learn About Diabetic Macular Edema (DME)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Diabetic Macular Edema (DME) Local Doctors?
Neil M. Bressler
Elite in Diabetic Macular Edema (DME)
Ophthalmology
Elite in Diabetic Macular Edema (DME)
Ophthalmology

The Johns Hopkins Hospital

1800 Orleans Street, Maumenee Lobby, Maumenee Lobby, 
Baltimore, MD 
Experience:
44+ years
Languages Spoken:
English

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Elite provider by MediFind in the treatment of Diabetic Macular Edema (DME). His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

Sobha Sivaprasad
Elite in Diabetic Macular Edema (DME)
Elite in Diabetic Macular Edema (DME)
11-43 Bath Street, 
London, ENG, GB 

Sobha Sivaprasad practices in London, United Kingdom. Sivaprasad is rated as an Elite expert by MediFind in the treatment of Diabetic Macular Edema (DME). Their top areas of expertise are Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Trabeculectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Ursula M. Erfurth-Schmidt
Elite in Diabetic Macular Edema (DME)
Elite in Diabetic Macular Edema (DME)
Vienna, AT 

Ursula Erfurth-Schmidt practices in Vienna, Austria. Ms. Erfurth-Schmidt is rated as an Elite expert by MediFind in the treatment of Diabetic Macular Edema (DME). Her top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal.

What are the latest Diabetic Macular Edema (DME) Clinical Trials?
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)

Summary: This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in parti...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

Summary: This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab...